Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2006-10-19
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of methotrexate (MTX).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Clinical diagnosis of active rheumatoid arthritis for at least 6 months and on a stable dose of methotrexate for at least 12 weeks

• Rheumatoid arthritis onset after 16 years of age

Exclusion Criteria:

• Any significant health problem other than rheumatoid arthritis

• History of male or female reproductive system cancer

• Clinically significant laboratory abnormalities